MAMU
VRTX icon

Myriad Asset Management US’s Vertex Pharmaceuticals VRTX Stock Holding History

Myriad Asset Management US’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,600
Closed -$3.55M – 39
2022
Q2 		$3.55M Buy
+12,600
New +$3.37M 0.82% 17

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Myriad Asset Management US's VRTX Position: Q3 2022 in Review

Myriad Asset Management US sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 12,600 shares — an estimated $3.55M sold.

Myriad Asset Management US first reported a position in VRTX in Q2 2022 and held it in 1 quarter. The position peaked at $3.55M in Q2 2022. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

  • Myriad Asset Management US reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Myriad Asset Management US sold 12,600 Vertex Pharmaceuticals shares in Q3 2022, an estimated $3.55M.
  • Myriad Asset Management US first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Myriad Asset Management US's Vertex Pharmaceuticals position peaked at $3.55M in Q2 2022.
  • 1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Myriad Asset Management US's 13F filing for Q3 2022, filed 14 Nov 2022.